ZKZuzana Keckesova

Zuzana Keckesova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zuzana Keckesova has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Juan M Gonzales-Morena

    Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic

    4 shared publications
  • Pavel Jakoube

    Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic

    4 shared publications
  • Andrea Hartmanova

    The Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic

    3 shared publications
  • Beata Malcekova

    Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences

    3 shared publications
  • Petra Kralova Viziova

    The Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic

    3 shared publications
  • Sara Escudeiro-Lopes

    Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences

    3 shared publications

Latest Publications

  • Open Access

    The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor

    by Sara Escudeiro-Lopes, Juan M Gonzalez-Morena, Alzbeta Baudysova, Michal Svoboda, Pavel Marasek, Gabriel Rodriguez-Gomez, Jessica Ferreira Mendes, Chung Weng Phang, Sravan Kumar Miryala, Pavel Jakoube, et al.

    Tumor suppressors represent one of the first lines of defense against malignant transformation, and their inactivation in cells leads to the onset of tumorigenesis. Cancer cells employ various mechanisms to inactivate cellular tumor suppressors, including epigenetic silencing and mutagenesis. Less understood are the mechanisms by which cancer cells inactivate tumor suppressors post-translationally. Here, we uncovered a previously undescribed post-translational mechanism by which cancer cells inactivate the potent mitochondrial tumor suppressor LACTB in breast cancers. We discovered that the substrate of LACTB can be LACTB itself; LACTB possesses autoproteolytic activity, which is important for modulating its tumor suppressor activity. We demonstrate that cancer cells exploit this feature of LACTB to induce LACTB’s self-degradation. This is mechanistically realized through upregulation of mitochondrial MRPS34 protein, which, through interaction with LACTB, is a positive regulator of LACTB’s autoproteolytic activity and a negative regulator of LACTB. This study provides insights into how cancer cells fine-tune the expression and activity of tumor suppressors to promote tumorigenesis.

  • Insights on Future Directions in Cancer Research from the 2025 AACR NextGen Stars

    by Edmond M. Chan, Yash Chhabra, Karen O. Dixon, Adam D. Durbin, Anniina Färkkilä, Anand D. Jeyasekharan, Zuzana Keckesova, John R. Prensner, Elvin Wagenblast, Stephanie Z. Xie, et al.


  • Open Access

    HIV-1 Infection Reduces NAD Capping of Host Cell snRNA and snoRNA

    by Barbora Benoni, Jiří František Potužník, Anton Škríba, Roberto Benoni, Jana Trylcova, Matouš Tulpa, Kristína Spustová, Katarzyna Grab, Maria-Bianca Mititelu, Jan Pačes, et al.

    Nicotinamide adenine dinucleotide (NAD) is a critical component of the cellular metabolism and also serves as an alternative 5' cap on various RNAs. However, the function of the NAD RNA cap is still under investigation. We studied NAD capping of RNAs in HIV-1-infected cells because HIV-1 is responsible for the depletion of the NAD/NADH cellular pool and causing intracellular pellagra. By applying the NAD captureSeq protocol to HIV-1-infected and uninfected cells, we revealed that four snRNAs (e.g., U1) and four snoRNAs lost their NAD cap when infected with HIV-1. Here, we provide evidence that the presence of the NAD cap decreases the stability of the U1/HIV-1 pre-mRNA duplex. Additionally, we demonstrate that reducing the quantity of NAD-capped RNA by overexpressing the NAD RNA decapping enzyme DXO results in an increase in HIV-1 infectivity. This suggests that NAD capping is unfavorable for HIV-1 and plays a role in its infectivity.


  • Open Access

    Correction: LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug

    by Valentina Cutano, Jessica Marianne Ferreira Mendes, Sara Escudeiro-Lopes, Susana Machado, Judith Vinaixa Forner, Juan M Gonzales-Morena, Martin Prevorovsky, Viacheslav Zemlianski, Yuxiong Feng, Petra Kralova Viziova, et al.

    We show the ability of LACTB to function as a tumor suppressor in ovarian cancer through down-regulation of Slug and induction of differentiation.

  • Open Access

    LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug

    by Valentina Cutano, Jessica Marianne Ferreira Mendes, Sara Escudeiro-Lopes, Susana Machado, Judith Vinaixa Forner, Juan M Gonzales-Morena, Martin Prevorovsky, Viacheslav Zemlianski, Yuxiong Feng, Petra Kralova Viziova, et al.

    Epithelial–mesenchymal transition (EMT) is a cellular mechanism used by cancer cells to acquire migratory and stemness properties. In this study, we show, through in vitro, in vivo, and 3D culture experiments, that the mitochondrial protein LACTB manifests tumor suppressor properties in ovarian cancer. We show that LACTB is significantly down-regulated in epithelial ovarian cancer cells and clinical tissues. Re-expression of LACTB negatively effects the growth of cancer cells but not of non-tumorigenic cells. Mechanistically, we show that LACTB leads to differentiation of ovarian cancer cells and loss of their stemness properties, which is achieved through the inhibition of the EMT program and the LACTB-dependent down-regulation of Snail2/Slug transcription factor. This study uncovers a novel role of LACTB in ovarian cancer and proposes new ways of counteracting the oncogenic EMT program in this model system.


  • Open Access

    LACTB induces cancer cell death through the activation of the intrinsic caspase-independent pathway in breast cancer

    by Juan M. Gonzalez-Morena, Sara Escudeiro-Lopes, Jessica Mariane Ferreira-Mendes, Pavel Jakoube, Valentina Cutano, Judith Vinaixa-Forner, Petra Kralova Viziova, Andrea Hartmanova, Radislav Sedlacek, Susana Machado, et al.

    Background: LACTB was recently identified as a mitochondrial tumour suppressor that negatively affects cancer cell proliferation by inducing cell death and/or differentiation, depending on the cell type and tissue. However, the detailed mechanism underlying the LACTB-induced cancer cell death is largely unknown. Methods: We used cell-based, either in 2D or 3D conditions, and in vivo experiments to understand the LACTB mechanisms. In this regard, protein array followed by an enrichment analysis, cell proliferation assays using different compounds, western blot analysis, flow cytometry and immunofluorescence were performed. Differences between quantitative variables following normal distribution were valuated using Student t test for paired or no-paired samples according to the experiment. For in vivo experiments differences in tumour growth were analyzed by 2-way ANOVA. Results: We show, that LACTB expression leads to cell cycle arrest in G1 phase and increase of DNA oxidation that leads to activation of intrinsic caspase-independent cell death pathway. This is achieved by an increase of mitochondrial reactive oxygen species since early time points of LACTB induction. Conclusion: Our work provides a deeper mechanistic insight into LACTB-mediated cancer-cell death and shows the dynamics of the cellular responses a particular tumor suppressive stimulus might evoke under different genetic landscapes.


  • Open Access

    Mitochondrial Tumor Suppressors—The Energetic Enemies of Tumor Progression

    by Pavel Jakoube, Valentina Cutano, Juan M. González-Morena, Zuzana Keckesova

    Tumor suppressors represent a critical line of defense against tumorigenesis. Their mechanisms of action and the pathways they are involved in provide important insights into cancer progression, vulnerabilities, and treatment options. Although nuclear and cytosolic tumor suppressors have been extensively investigated, relatively little is known about tumor suppressors localized within the mitochondria. However, recent research has begun to uncover the roles of these important proteins in suppressing tumorigenesis. Here, we review this newly developing field and summarize available information on mitochondrial tumor suppressors.